Cargando…

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

BACKGROUND: Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide maintenance therapy on overall survival in this setting has been inconsisten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Hockaday, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Gregory, Walter M, Morgan, Gareth J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318225/ https://www.ncbi.nlm.nih.gov/pubmed/30559051 http://dx.doi.org/10.1016/S1470-2045(18)30687-9

Ejemplares similares

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2019)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2020)

Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
por: Croft, James, et al.
Publicado: (2020)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
por: Striha, Alina, et al.
Publicado: (2018)

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
por: Coulson, Amy Beth, et al.
Publicado: (2022)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
por: Cook, Gordon, et al.
Publicado: (2019)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
por: Jones, John R., et al.
Publicado: (2019)

Molecular profiling in myeloma
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
por: Richardson, Paul G., et al.
Publicado: (2021)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
por: Bowcock, Stella, et al.
Publicado: (2023)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
por: de Arriba de la Fuente, Felipe, et al.
Publicado: (2022)

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
por: Du, Li, et al.
Publicado: (2022)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma
por: Schwamborn, Katharina, et al.
Publicado: (2011)

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
por: Shah, V, et al.
Publicado: (2018)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Activation of Coagulation by Lenalidomide-Based Regimens for the Treatment of Multiple Myeloma
por: Isozumi, Yu, et al.
Publicado: (2013)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma
por: Sagar, FNU, et al.
Publicado: (2018)

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
por: Moreau, Philippe, et al.
Publicado: (2019)

Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
por: Gao, Tiantao, et al.
Publicado: (2022)

Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons with Multiple Myeloma
por: Marchetti, Monia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g208c5bscjtv23i9shjujir8o9